SINGLE-CENTRE/OPEN LABEL, 24 WEEKS, PHASE I CLINICAL TRIAL OF ANCILLA DOMINI CAH-AGONIST INVERSE-TRANSCRIPTION THERAPEUTICS ON HYPERTENSION/CARDIAC ARRHYTHMIAS

Single-Centre/Open Label, 24 Weeks, Phase I Clinical Trial Of Ancilla Domini Chota-CAH Inverse-Transcription Therapeutics On Hypertension/Cardiac Arrhythmias

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202409832088067

Enrollment

Registered

2024-09-17

Start date

2024-11-12

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiology

Interventions

Ancilla Domini CHoTTA CAH

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults 18+ years old 2. Male/Female 3. Residents in any part of Ghana/beyond 4. Open to all nationalities/race 5. People diagnosed of: i. Hypertension ii. Cardiac Arrhythmias

Exclusion criteria

Exclusion criteria: 1. Children/under 18 years old 2. Pregnant/ Lactating Mothers

Design outcomes

Primary

Measure	Time frame
Over 80% Research candidates with Hypertension/Cardiac Arrhythmias shall be cured;All the research participants shall experience little/no intervention-associated side effects	—

Secondary

Measure	Time frame
Over 80% of the complications of Hypertension/Cardiac Arrhythmias that have not reached/exceeded their elastic limit (not completely demised) shall be halted/prevented/reversed in over 80% of research enrollees.;The Blood Pressure/Pulse Rate of over 80% of the participants with Hypertension /Cardiac Arrhythmias shall normalize	—

Countries

Ghana

Contacts

Public ContactAlee Geoffrey

Public Relations Executive of Ancilla Domini International Researchers

denudation2015@gmail.com2347041388422

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026